Today (April 7), Jinyu Bio-Technology Co.Ltd(600201) ( Jinyu Bio-Technology Co.Ltd(600201) , SH) announced that Chairman Zhang Zhenyu and director and president Zhang Jing planned to increase their holdings of A-Shares of the company with their own funds through centralized bidding trading through the trading system of Shanghai Stock Exchange.
At the same time, Jinyu Bio-Technology Co.Ltd(600201) also issued an announcement to terminate the non-public offering of shares to Inner Mongolia Jinyu biological Holding Co., Ltd. (hereinafter referred to as biological holding) with Zhang Jianyu and Zhang Jing’s father and daughter as the actual controllers.
Jinyu Bio-Technology Co.Ltd(600201) said that in view of the internal and external environmental changes and other factors, the company decided to terminate the non-public offering of A-Shares after full communication and careful analysis with relevant parties in order to comprehensively and effectively safeguard the interests of all shareholders in accordance with the overall planning of the company.
The reporter of the daily economic news noted that according to the non-public offering plan issued by 6 Zhejiang Kan Specialities Material Co.Ltd(002012) 021 in July, the price of non-public offering of shares by listed companies to biological holdings is 14.25 yuan / share. As of the closing on April 7, Jinyu Bio-Technology Co.Ltd(600201) share price was 11.46 yuan / share.
termination of non-public offering
According to the announcement of 6 Zhejiang Kan Specialities Material Co.Ltd(002012) 021 on July 8, the board of directors of the listed company deliberated and approved the proposal of non-public offering of A-Shares to specific objects. The issuing objects are biological holdings of shareholders holding more than 5% of the listed company, and Zhang Jianyu and Zhang Jing’s father and daughter are the actual controllers of biological holdings, forming a concerted action relationship with them.
Jinyu Bio-Technology Co.Ltd(600201) plans to issue no more than 631579 million shares (including the number of shares) to biological holdings at a price of 14.25 yuan / share, and the total amount of funds raised will not exceed 900 million yuan (including the number of shares).
At that time, Jinyu Bio-Technology Co.Ltd(600201) said that through the above subscription and nomination of board members, bio holdings would become the controlling shareholder of the listed company, and Zhang Jianyu and Zhang Jing’s father and daughter would become the actual controllers of the listed company, reflecting the determination of existing shareholders to support the company and their confidence in the future development of the company, which was conducive to the stable and sustainable development of the company.
However, on the evening of April 7, Jinyu Bio-Technology Co.Ltd(600201) announced that in view of the internal and external environmental changes and other factors, the company decided to terminate the non-public offering of A-Shares after full communication and careful analysis with relevant parties in order to comprehensively and effectively safeguard the interests of all shareholders in accordance with the overall planning of the company.
Jinyu Bio-Technology Co.Ltd(600201) said that the termination of the non-public offering of A-Shares is a prudent decision made by comprehensively considering the changes of internal and external environment and in combination with the actual situation. It will not have a significant impact on the company’s production, operation and business development, and there is no situation that damages the interests of the company and all shareholders, especially minority shareholders. After the termination of the non-public offering of a shares, the company will still maintain the original state of no controlling shareholder and no actual controller.
overweight + repurchase, can we reverse the downward trend of stock price
On the same day, Jinyu Bio-Technology Co.Ltd(600201) said that based on the firm confidence in the long-term sustainable and high-quality development of the company and the determination to continuously optimize the corporate governance structure by increasing the proportion of shares held by the company, chairman Zhang Zhenyu and director and president Zhang Jing decided to start the plan to increase the company’s shares through centralized bidding trading on the Shanghai stock exchange while the non-public offering was terminated.
Based on the above situation, on April 7, Jinyu Bio-Technology Co.Ltd(600201) received a notice that Chairman Zhang Zhenyu and director and president Zhang Jing planned to increase their holdings of A-Shares of listed companies with their own funds within 6 months from the date of disclosure of the shareholding increase plan. The way of increasing their holdings was centralized bidding trading through the trading system of Shanghai Stock Exchange.
Jinyu Bio-Technology Co.Ltd(600201) said that Zhang Jianyu, chairman of the board of directors and President of the company, and Zhang Jingji, director and President of the company, based on their firm confidence in the development prospect of the company and their recognition of the long-term investment value of the company. At the same time, in order to further promote the sustainable, stable and healthy development of the company, safeguard the interests of the company and all shareholders, stabilize market expectations and enhance investor confidence, this shareholding increase plan is hereby formulated.
Up to now, Zhang Jianyu holds 185382 million shares of the company, accounting for 1.65% of the total shares of listed companies; Zhang Jing holds 766800 shares of the company, accounting for 0.07% of the total shares of listed companies.
They plan to increase their holdings by no less than 30 million yuan (inclusive) and no more than 60 million yuan in total. There is no price range for the increase. Zhang Jianyu and Zhang Jing will gradually implement the increase plan based on the judgment of stock prices and comprehensively considering market fluctuations, capital arrangements and other factors.
At the same time, listed companies suggest that there may be risks that the shareholding increase plan cannot be implemented due to changes in the securities market and factors that cannot be predicted at present.
In the secondary market, Jinyu Bio-Technology Co.Ltd(600201) share price hit a record high of 30.94 yuan / share in August 2020, and then fluctuated all the way down. As of the closing on April 7, Jinyu Bio-Technology Co.Ltd(600201) reported at 11.46 yuan / share, nearly two-thirds lower than the high.
In addition to the repurchase plan of Zhang’s own father and daughter, it was also announced on July 201. The listed company plans to spend no less than 200 million yuan (inclusive) and no more than 300 million yuan (inclusive) to buy back shares for equity incentive within 12 months from the date when the board of directors deliberates and approves the share repurchase plan. The repurchase price does not exceed 18 yuan / share, and the number of shares repurchased is 111111 million to 166667 million.
